title: Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes.
abstract: BACKGROUND
  An impaired glomerular filtration rate (GFR) leads to end-stage renal disease and increases the risks of cardiovascular disease and death. Persons with type 1 diabetes are at high risk for kidney disease, but there are no interventions that have been proved to prevent impairment of the GFR in this population.
  
  
  METHODS
  In the Diabetes Control and Complications Trial (DCCT), 1441 persons with type 1 diabetes were randomly assigned to 6.5 years of intensive diabetes therapy aimed at achieving near-normal glucose concentrations or to conventional diabetes therapy aimed at preventing hyperglycemic symptoms. Subsequently, 1375 participants were followed in the observational Epidemiology of Diabetes Interventions and Complications (EDIC) study. Serum creatinine levels were measured annually throughout the course of the two studies. The GFR was estimated with the use of the Chronic Kidney Disease Epidemiology Collaboration formula. We analyzed data from the two studies to determine the long-term effects of intensive diabetes therapy on the risk of impairment of the GFR, which was defined as an incident estimated GFR of less than 60 ml per minute per 1.73 m(2) of body-surface area at two consecutive study visits.
  
  
  RESULTS
  Over a median follow-up period of 22 years in the combined studies, impairment of the GFR developed in 24 participants assigned to intensive therapy and in 46 assigned to conventional therapy (risk reduction with intensive therapy, 50%; 95% confidence interval, 18 to 69; P=0.006). Among these participants, end-stage renal disease developed in 8 participants in the intensive-therapy group and in 16 in the conventional-therapy group. As compared with conventional therapy, intensive therapy was associated with a reduction in the mean estimated GFR of 1.7 ml per minute per 1.73 m(2) during the DCCT study but during the EDIC study was associated with a slower rate of reduction in the GFR and an increase in the mean estimated GFR of 2.5 ml per minute per 1.73 m(2) (P<0.001 for both comparisons). The beneficial effect of intensive therapy on the risk of an impaired GFR was fully attenuated after adjustment for glycated hemoglobin levels or albumin excretion rates.
  
  
  CONCLUSIONS
  The long-term risk of an impaired GFR was significantly lower among persons treated early in the course of type 1 diabetes with intensive diabetes therapy than among those treated with conventional diabetes therapy. (Funded by the National Institute of Diabetes and Digestive and Kidney Diseases and others; DCCT/EDIC ClinicalTrials.gov numbers, NCT00360815 and NCT00360893.).
authors.forename: Ian H
authors.initials: IH
authors.lastname: de Boer
authors.forename: Wanjie
authors.initials: W
authors.lastname: Sun
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Cleary
authors.forename: John M
authors.initials: JM
authors.lastname: Lachin
authors.forename: Mark E
authors.initials: ME
authors.lastname: Molitch
authors.forename: Michael W
authors.initials: MW
authors.lastname: Steffes
authors.forename: Bernard
authors.initials: B
authors.lastname: Zinman
mesh_terms: D000328:Adult; D003404:Creatinine / Q000097:blood; D003922:Diabetes Mellitus, Type 1 / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D003928:Diabetic Nephropathies / Q000453:epidemiology; D005260:Female; D005500:Follow-Up Studies; D005919:Glomerular Filtration Rate / Q000187:drug effects*; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000008:administration & dosage*; D007328:Insulin / Q000008:administration & dosage*; D007332:Insulin Infusion Systems; D007676:Kidney Failure, Chronic / Q000453:epidemiology; D008297:Male; D008875:Middle Aged
chemical_list: D003404:Creatinine; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D007328:Insulin
references.citation: N Engl J Med. 2005 Dec 22;353(25):2643-53
references.pmid: 16371630
references.citation: JAMA. 2003 Oct 22;290(16):2159-67
references.pmid: 14570951
references.citation: N Engl J Med. 2001 Sep 20;345(12):851-60
references.pmid: 11565517
references.citation: Kidney Int. 1987 Apr;31(4):1012-8
references.pmid: 3295358
references.citation: Am J Kidney Dis. 2007 Feb;49(2 Suppl 2):S12-154
references.pmid: 17276798
references.citation: Kidney Int. 1995 Jun;47(6):1703-20
references.pmid: 7643540
references.citation: Diabetes Care. 2009 Oct;32(10):1833-8
references.pmid: 19587367
references.citation: Clin Chem. 2005 Apr;51(4):753-8
references.pmid: 15684277
references.citation: N Engl J Med. 1993 Sep 30;329(14):977-86
references.pmid: 8366922
references.citation: Ann Intern Med. 2011 Apr 19;154(8):554-9
references.pmid: 21502652
references.citation: Arch Intern Med. 2009 Jul 27;169(14):1307-16
references.pmid: 19636033
references.citation: Diabetes Care. 2011 Jan;34 Suppl 1:S11-61
references.pmid: 21193625
references.citation: JAMA. 2011 Jun 22;305(24):2532-9
references.pmid: 21693741
references.citation: J Am Soc Nephrol. 2009 Aug;20(8):1813-21
references.pmid: 19443635
references.citation: Am J Kidney Dis. 2009 Aug;54(2):205-26
references.pmid: 19577347
references.citation: Am J Med. 1985 May;78(5):785-94
references.pmid: 3993659
references.citation: Diabetologia. 1981 Oct;21(4):368-73
references.pmid: 7286497
references.citation: N Engl J Med. 2008 Jun 12;358(24):2545-59
references.pmid: 18539917
references.citation: N Engl J Med. 1985 Mar 7;312(10):617-21
references.pmid: 3883162
references.citation: N Engl J Med. 2001 Sep 20;345(12):861-9
references.pmid: 11565518
references.citation: Diabetes Care. 2010 Jul;33(7):1536-43
references.pmid: 20413518
references.citation: JAMA. 2005 Oct 12;294(14):1782-7
references.pmid: 16219881
references.citation: N Engl J Med. 1993 Nov 11;329(20):1456-62
references.pmid: 8413456
references.citation: Ann Intern Med. 2009 May 5;150(9):604-12
references.pmid: 19414839